Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb

Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb–IIIa inhibitors

Published:2011-01 Issue:2 Volume:146 Page:280-282
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Lin Gen-Min,Chu Kai-Min,Han Chih-Lu

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference12 articles.

1. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy;Vakeva;Circulation,1998

2. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial;Granger;Circulation,2003

3. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial;Verrier;JAMA,2004

4. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial;Mahaffey;Circulation,2003

5. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial;APEX AMI Investigators;JAMA,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial;American Heart Journal;2012-12

2. A critical appraisal of pexelizumab treatment in patients undergoing coronary artery bypass grafting;The Journal of Thoracic and Cardiovascular Surgery;2011-08

3. Predictors, moderators and mediators for the effectiveness of pexelizumab treatment in patients undergoing primary coronary revascularization;International Journal of Cardiology;2011-03